Member Info for roses

Uncanny - sorry but you are wrong.

In Ftse 100 and 250 stocks that would be correct - the buys and sells are directly matched i.e a buyer for every seller.

However on AIM there are 3 parties to every trade. The seller sells to the market maker, the market maker adjusts the price and may hold the shares for 1 minute or 1 month and will then sell to the buyer at their own discretionary rate.

Tozerk - They weren't buys they were delayed worked sells.

Do you honestly think the shareprice would be falling like it has if they were buys ?

Valju - you just posted "Maybe its NS rebuying his original 18 mill"

Are you suggesting he has sold up ?

Woody, it's a dose escalation study. they will keep upping the dose until it either reaches a maximum safe dose or it is decided that it has achieved the studies endpoints.

My point is that this latest escalation of the dose may not be the last, it may have to be escalated maybe one or two more times before this part of the trial can be concluded.

"concluding stages" plural, there is nothing telling us that a further dose escalation will not be required after this one

Hmm, Sign of efficacy has now been downgraded to signs of 'activity'

15 is a minor resistance with 21p being the next major resistance after that.

77k buy at 13.8p

level 2 is on the move up now, wins going gone to 13 - 14p

on Nex

55k delayed buy just shown, somethings brewing ?

Only about 6 weeks until the MULTIPLE winners are announced .

"We are thrilled to be on Cancer Research UK's Grand Challenge shortlist: this brings us one step closer to delivering a cancer vaccine template. We believe this approach will facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

Professor Lindy Durrant, Principal Investigator

"This research could result in a paradigm shift in the way we treat cancer. If successful, these templates for cancer treatment will allow doctors to easily identify which antigens to target, and then which type of vaccine to use, to create truly bespoke vaccines for each patient. As this type of treatment will be personalised based on each patient’s unique tumour, this could radically improve survival on a global scale."

CRUK 's thoughts :

"The academic-biotech-clinical partnerships in this application are really unique, the different perspectives that each discipline brings makes this team’s proposal comprehensive, innovative and therefore very powerful."

Lol, they dropped the price but both the live bid and ask went up at the same time.

Cheeky beggars

And another tick up 12.985 paid

ask going back up now, 36,379 just gone through on NEX

BS - I didn't say they I have never seen them before.

BS- it's definitely not a regulatory requirement and doubtful it's even considered best practice.

The only stocks in my portfolio that issue one such as this are a couple of FTSE 250 stocks, the vast majority in mine don't issue one.

Strange ?

still doesn't explain why they have given us news of news to come ?

It is out of place and a first from SCLP and is intriguing as to why ?

512k traded already this morning, quite unusual ?